Medicure, Inc. 是一家專注於心血管治療藥物之研究、臨床開發及商業化的製藥公司。公司總部位於加拿大曼尼托巴省溫尼伯市,目前聘有25名全職員工。公司主要致力於為美國市場的患者和處方醫生開發和推廣藥品及醫療保健產品。其業務重點是在美國市場推廣和分銷 AGGRASTAT(鹽酸替羅非班)注射劑和 ZYPITAMAG(匹他伐他汀)片劑,這些產品通過公司在美國的子公司 Medicure Pharma Inc. 進行銷售。公司還運營 Marley Drug Inc.(Marley Drug),這是一家藥房子公司,服務範圍涵蓋美國50個州、華盛頓特區和波多黎各。Marley Drug 致力於提升所有美國人獲得藥物的可及性,並提供優質的客戶服務和免費送貨上門服務。AGGRASTAT 適用於降低非ST段抬高急性冠狀動脈症候群患者血栓性心血管事件的發生率。此外,公司亦開發磷酸吡哆醛5'-磷酸類似物(P5P類似物)、其製備方法以及含有P5P類似物的組合物。
Based on comprehensive analyst evaluations, we have synthesized critical insights from expert assessments to outline a cautious outlook for MCUJF. Analysts note deteriorating fundamentals and challenging market sentiment, indicating potential downside risks in the near term. Following this expert analysis, we adopt a bearish stance on this stock. Our conclusion: MCUJF is a Sell candidate.
MCUJF stock price ended at $0.79 on 星期四, after dropping 13.19%
On the latest trading day Feb 12, 2026, the stock price of MCUJF fell by 13.19%, dropping from $0.79 to $0.79. During the session, the stock saw a volatility of 0.00%, with prices oscillating between a daily low of $0.79 and a high of $0.79. On the latest trading day, the trading volume for MCUJF decreased by 5.1K shares, aligning with the declining prices, which may indicate weakening market confidence in the near term. In total, 1.5K shares were traded, with a market value of approximately --.